MY008211A tablets Clinical Trials
3 recruitingDrug
Phase 33Phase 21
Showing 1–3 of 3 trials
Recruiting
Phase 3
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
Paroxysmal nocturnal haemoglobinuria (PNH)
Wuhan Createrna Science and Technology Co., Ltd66 enrolled2 locationsNCT06932744
Recruiting
Phase 3
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Paroxysmal nocturnal hemoglobinuria
Wuhan Createrna Science and Technology Co., Ltd20 enrolled1 locationNCT06932471
Recruiting
Phase 2Phase 3
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, PNH
Wuhan Createrna Science and Technology Co., Ltd120 enrolled1 locationNCT06933914